Korea Clinical Trial Strategy After MFDS 2025 Reforms: Why Korea is Becoming a Strategic Hub
The Korea clinical trial environment is no longer a peripheral consideration. In early 2025 the Korean Ministry of Food and Drug Safety (MFDS) implemented a sweeping overhaul of its new‑drug review system—introducing dedicated review teams, expanding the number of sponsor…